Topics:
Dermatology • Atopic Dermatitis
With the approval of oral JAK inhibitors such as Upadacitinib for atopic dermatitis, how are you considering its safety profile in comparison to traditional immunosuppressants such as prednisone, methotrexate, azathioprine, and mycophenolate?
Especially in the setting of these being more narrow acting than tofacitinib, should we consider them safer than our old drugs?
Answer from: at Community Practice
In every treatment situation, we need to help the patient understand the potential benefits and potential risks of a medication. In my opinion, Upadacitinib is in a completely different category than traditional immunosuppressants such as prednisone, methotrexate, azathioprine, and mycophenolate, si...
Sign in or Register to read more
Answer from: at Academic Institution
I agree with Dr. @Brian Keegan and would add the following: JAKi are actually generally safe if you look at the clinical trial data, especially compared to some of these less targeted immunosuppressants. However, when comparing to medications like dupilumab and talokinumab, the risk-benefit ratio cl...